Esketamine Improves Postoperative Emotions and Immune Function in Acoustic Neuroma Surgery

The trial indicates that sub-anesthetic doses of esketamine may significantly improve postoperative outcomes for acoustic neuroma patients, enhancing both emotional well-being and immune function. This positions esketamine as a potential adjunct therapy in surgical settings, warranting close observation for further developments in clinical applications.

The trial indicates that sub-anesthetic doses of esketamine may significantly improve postoperative outcomes for acoustic neuroma patients, enhancing both emotional well-being and immune function. This positions esketamine as a potential adjunct therapy in surgical settings, warranting close observation for further developments in clinical applications.

Trial Update

A randomized clinical trial found that sub-anesthetic doses of esketamine may enhance immune function and reduce negative emotions post-surgery in acoustic neuroma patients.

The trial indicates that sub-anesthetic doses of esketamine may significantly improve postoperative outcomes for acoustic neuroma patients, enhancing both emotional well-being and immune function. This positions esketamine as a potential adjunct therapy in surgical settings, warranting close observation for further developments in clinical applications.

Monitor further studies on esketamine's effects in different surgical populations and any regulatory changes regarding its use in perioperative settings.